Update September 2021: This trial remains active but is no longer recruiting.
An open-label, first line Phase II trial for inoperable, recurrent and metastatic cholangiocarcinoma (intra- and extrahepatic) and gall bladder cancer patients.
This will be a single arm study of first line Pembrolizumab and Gemcitabine/Cisplatin.
All patients on this trial will receive the immunotherapy drug Pembrolizumab in addition to the Gemcitabine/Cisplatin chemotherapy.
For more information on this trial, see: https://clinicaltrials.gov/ct2/show/NCT03260712Back to previous page